Published in BMJ on April 24, 2009
Recommendations on screening for cervical cancer. CMAJ (2013) 3.32
Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ (2012) 2.05
Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women. Am J Epidemiol (2013) 1.56
Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev (2013) 1.53
Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res (2012) 1.31
Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med (2014) 1.00
Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer (2014) 0.96
Cervical cancer screening in older women: new evidence and knowledge gaps. PLoS Med (2014) 0.80
At what age should cervical screening stop? BMJ (2009) 0.75
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol (2008) 6.20
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet (1997) 4.38
Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer (2003) 4.14
American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin (2006) 3.46
The epidemiology of genital human papillomavirus infection. Vaccine (2006) 3.28
Trends in cervical cancer and carcinoma in situ in Great Britain. Br J Cancer (1984) 3.05
Rationale for stopping cervical screening in women over 50. BMJ (1993) 3.01
Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer (1991) 2.18
Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer (2004) 1.88
Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol (2000) 1.82
Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol (2006) 1.77
International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer (1997) 1.50
Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer (2007) 1.30
Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet Gynecol (1993) 1.28
Screening for cervical cancer: recommendations and rationale. Am J Nurs (2003) 1.25
Invasive carcinoma of the uterine cervix following diagnosis and treatment of in situ carcinoma. Record linkage study within a National Cancer Registry. Radiother Oncol (1989) 1.22
The case for stopping cervical screening at age 50. Br J Obstet Gynaecol (1997) 1.12
Low efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer (1995) 1.08
Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996. Eur J Cancer (2002) 1.06
Cervical screening in women over the age of 50: results of a population-based multicentre study. BJOG (2004) 1.04
Cervical human papillomavirus screening among older women. Emerg Infect Dis (2005) 0.96
Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union. Int J STD AIDS (2005) 0.96
Low risk of cervical cancer during a long period after negative screening in the Netherlands. Br J Cancer (2003) 0.93
Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives. J Med Screen (2005) 0.93
Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer (2004) 0.89
Upper age limit for cervical screening. BMJ (1993) 0.86
Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial. Obstet Gynecol (2006) 0.85
Influences on the risk of recurrent high grade cervical abnormality. Int J Gynecol Cancer (2002) 0.83
Early discharge of low-risk women from cervical screening. J Public Health Med (2001) 0.81
Cervical cancer screening: American College of Preventive Medicine practice policy statement. Am J Prev Med (1997) 0.80
Does lowering the screening age for cervical cancer in The Netherlands make sense? Int J Cancer (2008) 0.80
Follow up after LLETZ: could schedules be modified according to risk of recurrence? BJOG (2001) 0.79
Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med (2012) 16.55
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 6.99
Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol (2011) 5.72
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet (2003) 4.20
A model for a smallpox-vaccination policy. N Engl J Med (2002) 3.79
Breast cancer mortality in Norway after the introduction of mammography screening. Int J Cancer (2012) 3.47
Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ (2005) 3.21
Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst (2010) 3.05
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol (2007) 2.59
Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol (2009) 2.59
Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev (2012) 2.39
Aging, retirement, and changes in physical activity: prospective cohort findings from the GLOBE study. Am J Epidemiol (2007) 2.36
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst (2009) 2.35
Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med (2014) 2.31
Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. Breast J (2006) 2.24
Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen (2012) 2.21
Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Gastrointest Endosc (2007) 2.18
Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ (2012) 2.05
Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol (2014) 2.04
Teaching communication with ethnic minority patients: ten recommendations. Med Teach (2011) 2.03
Individualizing colonoscopy screening by sex and race. Gastrointest Endosc (2009) 1.96
Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer (2005) 1.93
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst (2009) 1.89
Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect (2007) 1.89
Reliability and validity of the Infant and Toddler Quality of Life Questionnaire (ITQOL) in a general population and respiratory disease sample. Qual Life Res (2006) 1.88
At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer (2009) 1.88
Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2011) 1.85
Predicting the risk of a false-positive test for women following a mammography screening programme. J Med Screen (2007) 1.83
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst (2010) 1.83
National Polyp Study data: evidence for regression of adenomas. Int J Cancer (2004) 1.83
A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making (2011) 1.77
Patients' perceptions of the side-effects of prostate cancer treatment--a qualitative interview study. Soc Sci Med (2006) 1.76
Research recommendations for selected IARC-classified agents. Environ Health Perspect (2010) 1.73
Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ (2011) 1.72
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
Women's death in Scandinavia--what makes Denmark different? Eur J Epidemiol (2004) 1.69
Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol (2011) 1.66
Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroenterol Hepatol (2007) 1.65
Determinants of participation in colorectal cancer screening with faecal occult blood testing. J Public Health (Oxf) (2009) 1.62
Labeled versus unlabeled discrete choice experiments in health economics: an application to colorectal cancer screening. Value Health (2009) 1.61
African Programme For Onchocerciasis Control 1995-2015: model-estimated health impact and cost. PLoS Negl Trop Dis (2013) 1.61
Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol (2010) 1.61
No difference in HIV incidence and sexual behaviour between out-migrants and residents in rural Manicaland, Zimbabwe. Trop Med Int Health (2006) 1.60
Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc (2005) 1.58
Guidelines for the conduction of follow-up studies measuring injury-related disability. J Trauma (2007) 1.57
Occupation and bladder cancer among men in Western Europe. Cancer Causes Control (2003) 1.54
Prevalence and determinants of disabilities and return to work after major trauma. J Trauma (2005) 1.54
Anxiety and distress during active surveillance for early prostate cancer. Cancer (2009) 1.49
The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr (2006) 1.47
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen (2012) 1.46
Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer (2006) 1.45
Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. Value Health (2011) 1.44
Distribution and determinants of health and work status in a comprehensive population of injury patients. J Trauma (2004) 1.43
Has cytology become obsolete as a primary test in screening for cervical cancer? J Med Screen (2010) 1.42
Reliability and validity of the short form of the child health questionnaire for parents (CHQ-PF28) in large random school based and general population samples. J Epidemiol Community Health (2005) 1.41
Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer (2002) 1.41
[Overdiagnosis and overtreatment of breast cancer]. Ugeskr Laeger (2008) 1.40
[Preterm birth and low socioeconomic status: more psychosocial problems at age 5-6?]. Ned Tijdschr Geneeskd (2015) 1.39
[Degree of coverage of Danish health sciences research in the Science Citation Index, 1998]. Ugeskr Laeger (2004) 1.39
Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). Cancer (2008) 1.39
[Mammography screening without overdiagnosis]. Ugeskr Laeger (2004) 1.38
A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer (2009) 1.37
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer (2007) 1.37
Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys (2008) 1.36
Breast cancer incidence after the introduction of mammography screening: what should be expected? Cancer (2006) 1.35
Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst (2011) 1.33
Cancer incidence among firefighters: 45 years of follow-up in five Nordic countries. Occup Environ Med (2014) 1.33
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Estimating the benefits of mammography screening: the impact of study design. Epidemiology (2007) 1.32
Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer (2004) 1.31
Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer (2007) 1.30
Fertility pattern does not explain social gradient in breast cancer in denmark. Int J Cancer (2004) 1.30
Mammography screening in the county of Fyn. November 1993-December 1999. APMIS Suppl (2003) 1.27
Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst (2002) 1.24
Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med (2010) 1.24
Prevalence and prognostic factors of disability after childhood injury. Pediatrics (2005) 1.23
Mammography screening in Denmark. Dan Med Bull (2011) 1.22
E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut (2010) 1.22
Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ (2013) 1.20
Socioeconomic status and breast cancer in Denmark. Int J Epidemiol (2003) 1.19
Developing and interpreting models to improve diagnostics in developing countries. Nature (2006) 1.18